How Does Cencora Stock Stack Up Against Its Peers?
Cencora‘s stock has outperformed many peers over the past year, but how does it truly stack up against key distributors? As of December 2, 2025, a closer look reveals solid revenue growth and moderate operating margins, yet a higher valuation and lower free cash flow efficiency. Its upside may be limited if peers with stronger profitability and lower P/E ratios continue to attract investor preference. Cencora, formerly known as AmerisourceBergen until its 2023 rebranding, is a global pharmaceutical distribution company that connects manufacturers with healthcare providers, also offering logistics, data analytics, and consulting services.
- COR’s 1.2% operating margin, trailing HSIC (5.9%), reflects the tight profitability inherent in pharmaceutical distribution.
- COR’s 11.6% LTM revenue growth, strong vs. CAH, HSIC but lags MCK, OMI, reflecting varied specialty pharma and home healthcare market exposures.
- COR’s 41.4% stock gain and 30.6 PE, despite CAH’s stronger returns, signals high investor confidence in future specialty pharma growth.
Here’s how Cencora stacks up across size, valuation, and profitability versus key peers.
| COR | CAH | MCK | HSIC | OMI | |
|---|---|---|---|---|---|
| Market Cap ($ Bil) | 68.0 | 48.8 | 102.9 | 8.6 | 0.2 |
| Revenue ($ Bil) | 316.7 | 222.6 | 387.1 | 12.9 | 12.7 |
| PE Ratio | 30.6 | 23.9 | 23.8 | 20.4 | -0.3 |
| LTM Revenue Growth | 11.6% | -1.9% | 17.2% | 3.5% | 92.4% |
| LTM Operating Margin | 1.2% | 1.0% | 1.4% | 5.9% | 2.6% |
| LTM FCF Margin | 0.4% | 0.8% | 1.6% | 2.8% | -2.8% |
| 12M Market Return | 41.4% | 69.9% | 34.1% | -6.3% | -81.0% |
For more details on Cencora, read Buy or Sell COR Stock. Below we compare COR’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| COR | 11.6% | – | 12.1% | 9.9% | 11.5% |
| CAH | -1.9% | -1.9% | 10.7% | 13.0% | |
| MCK | 17.2% | 16.2% | 11.7% | 4.8% | |
| HSIC | 3.5% | – | 2.7% | -2.4% | 2.0% |
| OMI | 92.4% | – | 3.6% | 3.8% | 1.7% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| COR | 1.2% | – | 1.1% | 1.0% | 1.2% |
| CAH | 1.0% | 1.0% | 0.9% | 0.9% | |
| MCK | 1.4% | 1.3% | 1.4% | 1.7% | |
| HSIC | 5.9% | – | 5.8% | 5.6% | 6.9% |
| OMI | 2.6% | – | 2.8% | 2.9% | 2.8% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| COR | 30.6 | – | 29.6 | 23.8 | 20.3 |
| CAH | 23.9 | 18.3 | 29.0 | 60.8 | |
| MCK | 23.8 | 22.0 | 20.5 | 14.9 | |
| HSIC | 20.4 | – | 22.5 | 23.8 | 20.2 |
| OMI | -0.3 | – | -2.8 | -35.4 | 65.0 |
Still not sure about COR stock? Consider portfolio approach.
A Multi Asset Portfolio Gives You Safer Smarter Growth
Individual stocks can soar or tank but multi asset exposure steadies the ride. A spread out portfolio captures upside while limiting the damage from any one market.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices